

## ASX ANNOUNCEMENT

### Notification of closing date for Director nominations

**16 September 2021.** Analytica Ltd (ASX:ALT) is pleased to announce that its 2021 Annual General Meeting ("AGM") is expected to be held on Thursday 25 November 2021 at 10am (AEST) in Brisbane QLD. Final details relating to the meeting will be advised in the Notice of Meeting which will be despatched one month prior to the meeting date.

For the purpose of ASX Listing Rule 3.13.1, ALT advises that the closing date for nominations for position of director will be 24 September 2021. All nominations must be received by 5.00pm (AEST) on the closing date. Nominations should be emailed to [nominations@analyticamedical.com](mailto:nominations@analyticamedical.com) before the closing date.

Authorised by the Board of Directors of Analytica Ltd.

For more information, please contact: [investorrelations@analyticamedical.com](mailto:investorrelations@analyticamedical.com)

For more information about the PeriCoach System, visit: [www.PeriCoach.com](http://www.PeriCoach.com)

For more information about Analytica, visit [www.AnalyticaMedical.com](http://www.AnalyticaMedical.com)

#### About Analytica Limited

Analytica is a product development and commercialisation company, based in Queensland, Australia, focussed on Class I and II medical device products.

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance in Australia and has CE mark and USFDA 510(k) clearance for the treatment of urinary incontinence.

PeriCoach also has clearance in Australia, and CE Marking in Europe for the treatment of mild to moderate pelvic organ prolapse, a condition that affects up to 1 in 5 women during their lifetime.

Analytica is also the developer of the Enhanced Infusion System (EIS), a combination of patented technologies developed under the project names AutoStart and AutoFlush. The EIS is a simple and inexpensive IV add-in technology to reduce nursing monitoring costs, reduce embolism risk, improve infection control, and automatically restart flow after medication delivery during intravenous fluid infusion.

